A new paradigm to explain glaucoma is rapidly emerging, and it is generating brain-based treatment advances that may ultimately vanquish the disease known as the “sneak thief of sight.” A review now available in Ophthalmology, the journal of the American Academy of Ophthalmology, reports that some top researchers no longer think of glaucoma solely as an eye disease. Instead, they view it as a neurologic disorder that causes nerve cells in the brain to degenerate and die, similar to what occurs in Parkinson disease and in Alzheimer’s. The review, led by Jeffrey L Goldberg, M.D., Ph.D., assistant professor of ophthalmology at the Bascom Palmer Eye Institute and Interdisciplinary Stem Cell Institute, describes treatment advances that are either being tested in patients or are scheduled to begin clinical trials soon.
A study of the 5.3 million men and women seen in Department of Veterans Affairs outpatient clinics in a one-year period found that use of cocaine is predictive of open-angle glaucoma, the most common type of glaucoma.
Contact: Toni Baker
Medical College of Georgia
AUGUSTA, Ga. – An eye under pressure appears to express a unique set of proteins that physicians hope will one day help them better diagnose and treat glaucoma.
Contact: Michael Bernstein
415-978-3504 (Meeting, March 21-25)
202-872-6042 (After March 25)
American Chemical Society
SAN FRANCISCO, March 24, 2010 Â— Scientists are reporting progress toward a test that could revolutionize the diagnosis of glaucoma Â— the second leading cause of vision loss and blindness worldwide Â— by detecting the disease years earlier than usually happens at present. They reported the findings here today at the 239th National Meeting of the American Chemical Society (ACS).